Pipeline Update

FURTHER POSITIVE PHASE II CLINICAL TRIAL RESULTS FOR JUVISTA AND PIPELINE UPDATE Renovo Group plc (LSE: RNVO), the biopharmaceutical company developing drugs for the prevention an

FURTHER POSITIVE PHASE II CLINICAL TRIAL RESULTS FOR JUVISTA AND PIPELINE UPDATE Renovo Group plc (LSE: RNVO), the biopharmaceutical company developing drugs for the prevention and reduction of scarring at multiple body sites, is today giving an update on its drug pipeline. As part of this update Renovo is pleased to announce positive Phase II clinical trial results for its lead drug, Juvista, in a 12 month proof of concept study of scar reduction in split thickness skin graft donor sites (trial 1007). A briefing for analysts and investors will be presented by Professor Mark Ferguson, CEO of Renovo Group plc, at 10.00am today at the offices of Buchanan Communications, 45 Moorfields, London, EC2Y 9AE. Juvista Juvista is a therapeutic application of human recombinant TGFβ3 which has been shown in clinical trials to markedly improve subsequent scar appearance in the skin. As indicated at flotation, Renovo has now reported the results of two Phase II studies (1007 & 1011) in the second half of 2006. Both trials delivered statistically significant efficacy results. Clinical Trial 1007 – split thickness skin graft donor sites

  • Statistically significant reduction in scarring in Juvista treated split thickness skin graft donor sites compared to placebo (p=0.03)
  • 12 month study indicates a permanent improvement of scar appearance
  • Effective given as an injection followed by topical application at the time of surgery and topical application one day later
  • This proof of concept study is the first time Juvista has been administered to open wounds (split thickness skin graft donor sites) and is in contrast to previous trials in incisional wounds closed by suture or steri strips
  • Continued excellent safety and tolerability profile

Clinical trial 1007 was a fully randomised, double-blind, placebo controlled Phase II study designed to investigate the safety, tolerability, systemic exposure, and anti-scarring potential of Juvista in split thickness skin graft donor sites. Clinical assessment by plastic surgeons at 12 months following administration of Juvista demonstrated a statistically significant reduction in scarring compared to placebo (p= 0.03) and indicated a permanent regeneration of more normal skin. This trial demonstrates, for the first time, the efficacy of Juvista in the reduction of scarring in large open wounds whose margins are not approximated and sutured. These wounds are more easily treated with a topical application of Juvista rather than injection which is ideal for sutured wounds. Development of a topical formulation of Juvista would offer the prospect of additional indications such as reducing scarring in split thickness skin graft donor sites, grafts and burns which are markets of high medical need. Juvista injection for closed wounds following incisions/excisions however, remains Renovo’s primary target market as this represents the vast majority of surgical procedures each year (estimated to be at least 42 million procedures per year in the USA alone). Clinical Trial 1011 – incisional wounds In September this year Renovo announced highly statistically significant results (p<0.0001) from clinical trial 1011. The findings from this trial are particularly relevant to the major market of scar reduction following surgery and wound closure. Trial 1011 demonstrated that scars from incisional wounds injected with 200ng/100uL/linear cm of Juvista given either once or twice show a marked improvement in appearance compared to placebo. This was first evident at 4-7 months and was maintained or further improved at 12 months, indicating a permanent regeneration of more normal skin. These two new positive clinical trial results (1007, 1011) build on previous positive Renovo Phase II trial results presented at the time of IPO. Ongoing trials Trials for breast augmentation (1010) and mole removal (1008) are fully recruited, in follow-up phase and due to report in 2008. Scar revision trial (1009) started in H1 2006. A multicentre trial in breast reduction (0041) was initiated in the first half of 2006. Two trials confirming the dose response with Cambrex manufactured TGFβ3 have also started: trial 0050 has fully recruited and the follow-on trial 0036 is in mid-recruitment. Planned trials to support the fast track indication of surgical revision of disfiguring scars A fast track application has recently been submitted to the FDA with a protocol for a pilot study of scar prevention following keloid excision. This is anticipated to be Renovo’s first trial in the United States. To provide potential partners with an opportunity to contribute to protocol design of a large multinational series of scar revision trials (0060-0063) which are strategically important and expensive, Renovo has decided to slightly delay initiation of this set of trials until the first half of 2007, after a partnering deal is likely to have been concluded. As a result of this strategy a rolling BLA (Biologics License Application) submission for the indication of the surgical revision of disfiguring scars is anticipated to commence in 2007 and conclude with the clinical dossier in H1 2009. Planned trials to support the general (cosmetic) indication of scar improvement Trials for breast augmentation (1010) and mole removal (1008) are fully recruited, in follow-up phase and due to report in 2008. The clinical trial for the prevention of scarring following bilateral varicose vein surgery (0042) has started in the UK, which is scheduled to recruit the majority of patients. Centres in the United States, where the operation is less common, may be added in H1 2007 after the results of a pre-clinical study have been reported to the FDA. Phase III trials for the general scar reduction indication are scheduled to begin in H2 2007 and are currently planned to be for the prevention of scarring following mole removal and breast augmentation surgery (pending end of Phase II discussions with the regulatory authorities). BLA submission for the broader general scar reduction label remains on track for 2009. Zesteem Zesteem is a novel formulation of estradiol and accelerates re-epithelialisation following surgery or wounding. The first Phase III clinical trial in split thickness skin graft donor sites (0066) will be initiated in H2 2006. Juvidex Juvidex, a formulation of Mannose-6-Phosphate (M6P), inhibits the activation of TGFβ1 and TGFβ2 resulting in an improvement of subsequent scarring. The current Phase II efficacy trial in the skin will report in H2 2006. Juvidex will likely be differentiated for prevention of scarring in indications outside the skin. Initial clinical trials will likely focus on the eye or tendons and will commence at the end of 2007 or beginning of 2008. Prevascar Prevascar is a formulation of human recombinant Interleukin 10 (IL-10) which modulates the inflammatory response resulting in an improvement in subsequent scarring. The current Phase II efficacy trial in the skin will report in H1 2007. An initial clinical trial for the prevention of scarring following nerve injury is being planned. Preclinical Renovo continues to discover new molecules and targets and to file appropriate patent applications. Commenting on Renovo’s pipeline and today’s new clinical trial data, Professor Mark Ferguson, Chief Executive Officer, said: “We are extremely pleased with the progress we’ve made on our pipeline. Today’s new clinical trial data (1007) for Juvista provides us with statistically significant efficacy data using a proof of concept topical administration to split thickness skin graft donor sites – potentially opening up an additional new market opportunity for us in open wounds, for example following burn injury. “These positive data for split thickness skin graft donor sites follow our recent announcement of highly statistically significant results from Trial 1011 where Juvista improved the scar appearance following surgical incisions. These two positive trials further support the statistical and clinical effectiveness of Juvista in the reduction of scarring. “This quarter we have delivered two more positive trial results for Juvista and made excellent progress in our goal to be first to market with a drug to reduce scarring in the skin.” Today’s web cast Simultaneous with the meeting at 10.00 am, there will be a live audio web cast of the presentation. To connect to the web cast facility, please go to the Company’s website www.renovo.com approximately 10 minutes (09:50 am) before the start of the briefing. Preliminary results Renovo will announce its preliminary results for the year ending 30 September 2006 on 14 December 2006. For further information please contact: Renovo Group plc Professor Mark Ferguson, Chief Executive Officer +44 (0) 161 606 7222 Simon Bielecki, Head of Communications +44 (0) 161 606 7328 Buchanan Communications Tim Anderson/Lisa Baderoon/Mary-Jane Johnson +44 (0) 20 7466 5000 Trial 1007 background This trial (1007) was a fully randomised, double-blind, placebo controlled Phase II study to investigate the safety, toleration, systemic exposure, and anti-scarring potential of Juvista in split thickness skin graft donor sites in 97 male subjects aged 18-85 years. The within person trial design used a placebo or standard care control compared to a 50ng/cm² injection of Juvista or 50ng/cm² injection plus 100ng/cm² topical application of Juvista. Subjects were assigned to one of three groups. Each subject had two 3cm² split thickness skin graft donor sites harvested using a dermatome from the lower back. Split thickness skin graft donor sites were randomly assigned to Juvista or placebo treatment. Clinical assessment of scarring of the donor sites at 12 months showed the Juvista treated sites (injection and topical) to be statistically significantly improved compared to placebo. About Renovo Renovo is a biopharmaceutical product company and is the world leader in scar prevention and reduction research, and the development of drugs to prevent and reduce scarring. The Company has a highly skilled management team with over 30 years of research in the field of scarring, and significant pharmaceutical industry experience. Renovo has a portfolio of drugs which exploit different novel mechanisms of action to prevent and reduce scarring at multiple body sites and to accelerate healing. The Company’s deep pipeline includes four drugs in phase II clinical development, a further four advanced pre-clinical candidates and nine other pre-clinical candidates. Scarring can result from acute injury in, or surgery to, the skin, blood vessels, eyes, nerves, internal organs, tendons and ligaments. These are high value markets of significant unmet medical need. Renovo aims to be first to market with a pharmaceutical drug in the US and Europe to prevent and reduce scarring. Current demand is inadequately met and there is no near term competition. According to external research conducted by The Mattson Jack Group, the potential commercial market for prevention and reduction of scarring in the skin is worth in the order of US$4 billion per annum in the US alone.

Holding(s) in Company

RENOVO GROUP PLC (“the Company”) 26 October 2006 Holding in Company The Company has received notification from Fidelity International on the dates indicated below that the legal entities listed b

RENOVO GROUP PLC (“the Company”) 26 October 2006 Holding in Company The Company has received notification from Fidelity International on the dates indicated below that the legal entities listed below are interested in ordinary shares of 10p each of the Company’s issued share capital in the amounts listed below.

Date of Notification Date Company received Notification FMR Corp. and its direct and indirect subsidiaries FIL and its direct and indirect subsidiaries TOTAL Number of ordinary shares TOTAL Ownership Percentage
25 October 2006 26 October 2006 12,698,363 10,592,908 23,291,271 13.15%
Change in Holding since last notification +279,453 - -

Contacts Goldman Sachs - Howard Rowe 0207 774 1000 Nomura Code – Chris Collins 0207 776 1207 Buchanan Communications - Tim Anderson 07710 328 560 Renovo Group plc – Simon Bielecki 0161 606 7332 END

Holding in Company

RENOVO GROUP PLC (“the Company”) 2nd November 2006 Holding in Company The Company has received notification from the Goldman Sachs Group, Inc.

RENOVO GROUP PLC (“the Company”) 2nd November 2006 Holding in Company The Company has received notification from the Goldman Sachs Group, Inc. (GS Inc) on the date indicated below that the legal entities listed below are interested, by attribution only,in ordinary shares of 10p each of the Company’s issued share capital in the amounts listed below.

Date of Notification Date Company received Notification Goldman, Sachs & Co., a wholly owned subsidiary of GS Inc Goldman Sachs International, a wholly owned subsidiary of GS Inc TOTAL Number of ordinary shares held by Goldman Sachs Inc TOTAL Ownership Percentage
1 November 2006 2 November 2006 17,270,476 2,810,761 6,170,347 11.3%
Change from last notification - - -

Contacts Goldman Sachs - Howard Rowe 0207 774 1000 Renovo Group plc – Robin Cridland 0161 606 7332

Holding(s) in Company

RENOVO GROUP PLC (“the Company”) 6th November 2006 Holding in Company The Company has received notification from JP Morgan Partners, LLC ("JPMP")of 1221 Avenue of the Americas, New York, NY, Un

RENOVO GROUP PLC (“the Company”) 6th November 2006 Holding in Company The Company has received notification from JP Morgan Partners, LLC ("JPMP")of 1221 Avenue of the Americas, New York, NY, United States that JPMP has decreased its material interest in the share capital of Renovo Group plc to 6%. Details are as follows: Number of shares sold: 5,322,947 (3.0%) Total number of shares held by JP Morgan Partners, LLC: 10,645,894 (6.00%). Contacts

Holding(s) in Company

RENOVO GROUP PLC (“the Company”) 7 November 2006 Holding in Company The Company has received notification from Atlas Venture on the date indicated below that the legal entities listed below are i

RENOVO GROUP PLC (“the Company”) 7 November 2006 Holding in Company The Company has received notification from Atlas Venture on the date indicated below that the legal entities listed below are interested in ordinary shares of 10p each of the Company’s issued share capital in the amounts listed below.

Date of Notification Atlas Venture Fund V, L.P. Atlas Venture Fund V-A, C.V. Atlas Venture Fund V-A, L.P. TOTAL Number of ordinary shares TOTAL Ownership Percentage
6 November 2006 17,940,689 4,457,581 298,137 22,696,407 12.8%
Change in Holding since last notification -4,330,093 -1,075,864 -71,957

For further information please contact Renovo Group plc – Simon Bielecki, Head of Communications 0161 606 7328

Notification of Preliminary Results

RENOVO GROUP PLC PRELIMINARY RESULTS NOTIFICATION Renovo Group plc (LSE: RNVO), the biopharmaceutical company developing drugs for the prevention and reduction of scarring at mult

RENOVO GROUP PLC PRELIMINARY RESULTS NOTIFICATION Renovo Group plc (LSE: RNVO), the biopharmaceutical company developing drugs for the prevention and reduction of scarring at multiple body sites, will announce its preliminary results for the year ending 30 September 2006 on Thursday 14 December 2006. Professor Mark Ferguson, CEO, and Rob Cridland, Executive Director, Finance and Business Development & Company Secretary, will host a briefing for analysts at 09:30am on Thursday 14 December 2006 followed by a press briefing at 11:00am at the offices of Buchanan Communications, 45 Moorfields, London, EC2Y 9AE. Simultaneous to the meeting at 09:30am, there will be a live audio web cast of the preliminary results presentation. To connect to the web cast facility, please go to the Company’s website www.renovo.com approximately 5 minutes (09:25 am) before the start of the briefing. For further information please contact: Renovo Group plc Professor Mark Ferguson, Chief Executive Officer +44 (0) 161 606 7222 Simon Bielecki, Head of Communications +44 (0) 161 606 7328 Buchanan Communications Tim Anderson/Lisa Baderoon/Mary-Jane Johnson +44 (0) 20 7466 5000

Technology Pioneer 2007

RENOVO SELECTED BY THE WORLD ECONOMIC FORUM AS A TECHNOLOGY PIONEER FOR 2007 Renovo Group plc (LSE: RNVO), the biopharmaceutical company developing drugs for the prevention and red

RENOVO SELECTED BY THE WORLD ECONOMIC FORUM AS A TECHNOLOGY PIONEER FOR 2007 Renovo Group plc (LSE: RNVO), the biopharmaceutical company developing drugs for the prevention and reduction of scarring at multiple body sites, is pleased to announce that it has been selected by the World Economic Forum as one of the Technology Pioneers for 2007. The Company is initially focused on developing drugs for the prevention and reduction of scarring in the skin. Renovo will then look to extend its drug candidates to other body sites, such as the eye, tendons and nerves. Renovo receives this award having been recognised as developing and applying innovative technologies in the areas of biotechnology and health. This year’s class of companies were selected not only because of the cutting-edge work, but also because their work has potential long-term impact on business and society. The final selection of the 47 Technology Pioneers was made by a panel of world leading technology and venture capital experts appointed by the World Economic Forum. The winners were selected from a group of 225 nominees. Commenting on the award, Professor Mark W J Ferguson, Chief Executive Officer of Renovo, said: “We are delighted to be recognised by the World Economic Forum as a Technology Pioneer and believe that this endorsement will serve to boost our profile and reputation across the world as an innovative company developing first-in-class drugs. I look forward to participating in the World Economic Forum meeting in Davos next January.” Peter Torreele, Managing Director of the World Economic Forum. said: “The competition to become a Technology Pioneer has been more intense than ever. It is evident that technology and innovation is playing a key role in the shifting power equation at a global level. Driving this shift is the tremendous amount of innovation taking place outside of traditional hubs. The wide geographic spread of this year’s Technology Pioneers is a testament to this trend. We are pleased to welcome these exciting companies to our Community of Technology Pioneers, and look forward to engaging these industry leaders of the future into the community of the World Economic Forum.” For further information please contact: Renovo Group plc Professor Mark Ferguson, Chief Executive Officer +44 (0) 161 606 7222 Simon Bielecki, Head of Communications +44 (0) 161 606 7328 Buchanan Communications Tim Anderson/Lisa Baderoon/Mary-Jane Johnson +44 (0) 20 7466 5000 About Renovo Group plc Renovo is a biopharmaceutical product company and is the world leader in scar prevention and reduction research, and the development of drugs to prevent and reduce scarring. The Company has a highly skilled management team with over 30 years of research in the field of scarring, and significant pharmaceutical industry experience. Renovo has a portfolio of drugs which exploit different novel mechanisms of action to prevent and reduce scarring at multiple body sites and to accelerate healing. The Company’s deep pipeline includes four drugs in phase II clinical development, a further four advanced pre-clinical candidates and nine other pre-clinical candidates. Scarring can result from acute injury in, or surgery to, the skin, blood vessels, eyes, nerves, internal organs, tendons and ligaments. These are high value markets of significant unmet medical need. Renovo aims to be first to market with a pharmaceutical drug in the US and Europe to prevent and reduce scarring. Current demand is inadequately met and there is no near term competition. According to external research conducted by The Mattson Jack Group, the potential commercial market for prevention and reduction of scarring in the skin is worth in the order of US$4 billion per annum in the US alone. About the World Economic Forum The World Economic Forum (http://www.weforum.org), based in Geneva, Switzerland, is an independent organization committed to improving the state of the world. Funded by the contributions of 1,000 of the world's foremost corporations, the Forum acts in the spirit of entrepreneurship in the global public interest to further economic growth and social progress. The Forum serves its members and society by creating partnerships between and among business, political, intellectual and other leaders of society to define, discuss and advance key issues on the global agenda. Incorporated in 1971 as a foundation, the World Economic Forum is impartial and not-for-profit, and is tied to no political, partisan or national interests. In 1995 the Forum was awarded NGO consultative status with the Economic and Social Council of the United Nations. About the Technology Pioneers To be selected as a Technology Pioneer, a company must be involved in the development of life-changing technology innovation and have the potential for long-term impact on business and society. In addition, it must demonstrate visionary leadership, show all the signs of being a long-standing market leader – and its technology must be proven. Previous Technology Pioneers have included Autonomy, Cambridge Silicon Radio, Encore Software, Google, Millennium Pharmaceuticals and Napster. The pioneering companies’ products include microscopic pill cameras, bio sensors that localize landmines, implantable medical devices for the treatment of brain tumours, mobile television service, anti-scarring drugs, open source webrowsers, video headsets, thin-film diamond coatings, solar air-conditioner equipment, paper batteries for music-playing greeting cards, and even an automatic and compacting trash bin powered by solar energy. The selection criteria include: 1) Innovation. The company’s technology must be truly innovative. A new version or repackaging of an already well-accepted technological solution does not qualify as an innovation. The innovation should be recent – not more than two years old. The company should invest significantly in R&D. 2) Potential Impact. This company’s technology must have the potential to have a substantial long-term impact on business and society in the future. 3) Growth and Sustainability. The company should have all the signs of being a long-term market leader and should have well-formulated plans for future development and growth. 4) Proof of Concept. The company must have a product on the market or have proven practical applications of the technology. Companies in “stealth” mode and companies with untested ideas or models will not qualify. 5) Leadership. The company must have visionary leadership that plays a critical role in driving the company towards reaching its goals. 6) Status. The company must not currently be a Member of the World Economic Forum. This criterion applies to the parent company – thus wholly-owned subsidiaries of large firms are not eligible. Go to www.weforum.org/techpioneers/2007 for the entire list of Technology Pioneers and interviews with the CEOs of the selected companies. For more specific information, please e-mail: tech.pioneers@weforum.org Download print-quality high resolution photographs of the CEOs of the selected companies at: www.pbase.com/forumweb/techpioneers2007

Holding(s) in Company

RENOVO GROUP PLC (“the Company”) Holding in Company The Company has received notification that, as at close of business on 7 December 2006, the Goldman Sachs Group, Inc.

RENOVO GROUP PLC (“the Company”) Holding in Company The Company has received notification that, as at close of business on 7 December 2006, the Goldman Sachs Group, Inc. (GS Inc) was interested, by attribution only, in 5,552,775 Renovo ordinary shares. Of these 5,552,775 shares: • The interest in 1,307,335 shares arose from the interest held by Goldman Sachs & Co., a wholly-owned direct subsidiary of GS Inc, acting as a custodian for its customers. • The interest in 4,245,440 shares arose from a beneficial interest held by Goldman Sachs International, a wholly-owned indirect subsidiary of GS Inc. Contact Renovo Group plc – Simon Bielecki 0161 606 7328

Holding(s) in Company

RENOVO GROUP PLC (“the Company”) 19 December 2006 Holding in Company The Company has received notification from HealthCap IV GP SA on the date indicated below that the legal entities listed below

RENOVO GROUP PLC (“the Company”) 19 December 2006 Holding in Company The Company has received notification from HealthCap IV GP SA on the date indicated below that the legal entities listed below are interested in ordinary shares of 10p each of the Company’s issued share capital in the amounts listed below.

Date of Notification HealthCap IV Bis, L.P. HealthCap IV, L.P. HealthCap IV IV, KB OFCO Club IV TOTAL Number of ordinary shares TOTAL Ownership Percentage
19 December 2006 8,099,875 11,209,516 817,987 306,631 20,434,009 11.53%
Change in Holding since last notification -839,260 -1,161,463 -84,755 -31,771 -2,117,249

For further information please contact Renovo Group plc – Simon Bielecki, Head of Communications 0161 606 7328

2006 Annual Report

RENOVO GROUP PLC Copies of the 2006 Annual Report, notice of Annual General Meeting and proxy form have been submitted and will shortly be available for inspection at the UK Listing Authority's do

RENOVO GROUP PLC Copies of the 2006 Annual Report, notice of Annual General Meeting and proxy form have been submitted and will shortly be available for inspection at the UK Listing Authority's document viewing facility situated at the Financial Services Authority, 25 The North Colonnade, Canary Wharf, London E14 5HS. For further information please contact: Simon Bielecki, Head of Communications +44 (0) 161 606 7328

Syndicate content